Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Yuma Regional Cancer Center Officially ... brings comprehensive cancer care to Yuma, Arizona. , ... Center has officially opened. A Mayo Clinic Care ... such as open, semi-private and private infusion rooms, ... Resource Center, hematology, rehabilitation center, a pain management ...
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 Adding ... their weighing boat special – Buy 2 ... free. This promotion will benefit lab technicians looking for ... Weighing boats are ideal for multiple applications including weighing ... a variety of choices including diamond-shaped, hexagonal, square, aluminum ...
(Date:7/29/2014)... hurdled a number of significant technological challenges in ... technology originally created for the James Webb Space ... Harvey Moseley, a scientist at NASA,s Goddard Space ... electrostatically actuated microshutter arrays that is, those ... as functional as the current technology,s magnetically activated ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... and his team are researching nano-scale cantilevers that have the ... gases in the air. Put them into a small handheld ... in battle, in industry, in health care and even at ... do this work has been something we,ve only seen so ...
... announced today the successful closure of its Starfish ... capital fundraising in,Australia. The fund will invest in ... of this fundraising is an endorsement of Starfish ... the development of,innovative companies that, with the right ...
... Calif., Nov. 12 Telik, Inc.,(Nasdaq: TELK ... TRAP(R) drug,discovery technology to investigators at the Hospital ... studies the mechanisms underlying,musculoskeletal and autoimmune diseases to ... use Telik,s TRAP technology to,discover novel compounds that ...
Cached Biology Technology:Clemson researchers advance nanoscale electromechanical sensors 2Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund 2Telik Announces New TRAP Drug Discovery Agreement 2
(Date:7/30/2014)... JOSE, Calif. , July 30, 2014 /PRNewswire/ ... partnership with the United States Air Force Research ... proposed by Binghamton University ... human performance monitoring (HPM). The $425,000 project, with ... electronics packaging firm i3 Electronics, Inc. ( ...
(Date:7/30/2014)... DCToday scientists unveiled the first high-resolution map of ... entire country of Per. The new and improved ... sea change for future market-based carbon economies. ... high ecological diversity and it provides the critical ... for conservation, land use, and enforcement purposes. The ...
(Date:7/30/2014)... paper published online today in the journal Scientific ... Evan Kodra and Auroop Ganguly found that while global ... in temperature extremes. For instance, while each year,s average ... will also tend to fall within a wider range ... currently being observed. This means that even as overall ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Big data confirms climate extremes are here to stay 2
... be hazardous for moose and men. According to estimates, millions ... America and Europe each year. Moose, in particular, venture to ... deicing. Because moose are the largest animal in ... their salt cravings can pose significant risks to human and ...
... The results presented in this book cover all from ... to humans, to case studies of the development of ... increasing populations for forests, and the beavers, relationship with ... water. Several chapters deal with the high degree ...
... The potential of microscopic organ-on-a-chip devices that mimic ... engineers can model the effects of therapies more accurately, ... Imperial College London this week. Professor Don ... Engineering at Harvard University, will deliver the inaugural Bagrit ...
Cached Biology News:Of moose and men 2Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London 2
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Rac 1/2/3/4 (S-18)...
... K+ Cl- Cotransporter-1 (KCC1). ... significant sequence homology with ... REACTIVITIES: The immunogen sequence ... human, mouse, porcine and ...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Biology Products: